The respiratory demands of china have increased due to a rise in air population and high rates of smoking in big cities. The British pharma has decided to render a sum of AUD 100 million which comes up to $77 million to its Sydney site with aim of extending the supply if respiratory medicines.
The money will be utilized by AstraZeneca to append three line of production to the eight lines that are in current use, and each of them will have the capacity to bring about more than 70 million units of asthma med PulmicortRespules every year. The company revealed that in the coming four years,the exports from the site will be expanded to AUD 2.4 billion which is $18 billion, with the aim to make the production of respules twice as large to 1 billion by the year of 2025.
During his visit to London, CEO Pascal Soriot declared the plan along with Malcolm Turnbull, Australian Prime Minister. As per the suggestions of a spokesperson from AstraZeneca, the enhancement is ongoing and will be functional by the initial months of the year 2019, they confirmed.
At present, AstraZeneca runs two facilities that are based near Shanghai in China, a manufacturing plant of pills and injectable in Wuxi and an oral and intravenous meds plant which is based 100,000-square meter based in Taizhou and is worth $200 million. However, the Australian site produces a huge amount of respiratory drugs that are supplied to the market. Presently, 90% of products are supplied to China by the Australian site. Even though, the cost of labor in China is less, it is challenging to clone the manufacturing technology, confirms Mark Morgan, manufacturing director of AstraZeneca Australia.
Regarding the country’s rise in demand for respiratory medicines the company believes this might be a case of Chronic Obstructive Pulmonary disease and severe pediatric asthma. As per the reports of China Asthma Alliance in 2013, in the past 10 years the rate of asthma in Shanghai and Beijing has increased by 1.9 times.